Relmada Therapeutics, Inc.
NASDAQ:RLMDBiotechnology
-$0.06 today
- Market cap
- $304.61M
- Beta
- 0.39
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.68
Volume 1.86M
Average 1.24M
RLMD Sales of Investments
Cash received from selling or redeeming investments.
Relmada Therapeutics, Inc.NASDAQ: RLMD
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments declines year over year
Q1 FY2026 sales of investments of $14.29M fell 9.8% year over year, ahead of the -45.3% change in trailing-twelve-month sales of investments. Sequentially, it rose 144.0% from the prior quarter. Over 3 fiscal years it compounded at -18.9% a year.
Context
- Sales of investments increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -9.8% holds above the trailing-twelve-month pace of -45.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 35.69M USD
- Year-over-year change
- -43.9%
- 4-year CAGR
- -32.2%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.69M | -43.9% |
| FY2024 | 2024-12-31 | 63.64M | -54.8% |
| FY2023 | 2023-12-31 | 140.92M | +110.2% |
| FY2022 | 2022-12-31 | 67.03M | -60.3% |
| FY2021 | 2021-12-31 | 168.86M | — |
Sales of Investments vs competitors
How RLMD compares with its peers on the latest reported figures
- RLMD's LTM Mar 2026 sales of investments of $34.13M is the 5th largest of the 9 companies compared; the peer median is $56.15M.
- Its year-over-year change of -45.3% is the 5th highest of 6, against a peer median of -23.2%.
- Over three fiscal years its annual growth of -18.9% compares with a peer median of -3.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $145.43M | -23.2% | -12.4% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $140M | -11.6% | +141.1% | — |
| LTM Mar 2026 | $125.25M | -43.8% | — | 1371.0% | |
| LTM Mar 2026 | $83M | +88.6% | — | — | |
| LTM Mar 2026 | $34.13M | -45.3% | -18.9% | — | |
| LTM Mar 2026 | $29.3M | -50.5% | -3.3% | 11.5% | |
| LTM Mar 2026 | $0 | — | — | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding RLMD) | $56.15M | -23.2% | -3.3% | 5.7% | |
Competitors are the stored peer set for RLMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (125.75M) | (157.04M) | (98.79M) | (79.98M) | (57.39M) |
| Depreciation & Amortization | 1.26K | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 40.49M | 44.19M | 43.81M | 30.19M | 14.96M |
| Change in Working Capital | (7.86M) | 10.59M | 3.08M | (1.58M) | (3.95M) |
| Accounts Receivables | 79.46K | (426.06K) | 512.43K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.85M | 421.04K | (1.76M) | 624.55K | (2.56M) |
| Other Working Capital | (10.79M) | 10.6M | 4.32M | (2.21M) | (1.39M) |
| Other Non-Cash Items | 1.25M | (1.55M) | 241.16K | (381.66K) | 586.18K |
| Operating Cash Flow | (91.87M) | (103.8M) | (51.66M) | (51.76M) | (45.79M) |
| Capital Expenditures | 0 | 0 | (4) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (222.98M) | (47.29M) | (90.46M) | (12.08M) | (83.83M) |
| Sales of Investments | 168.86M | 67.03M | 140.92M | 63.64M | 35.69M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (54.12M) | 19.73M | 50.45M | 51.56M | (48.14M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 185.31M | 42.73M | 0 | 246.75K | 93.64M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.63M | 2.29M | (98.46K) | (287.09K) | (73.02K) |
| Financing Cash Flow | 187.94M | 45.02M | (98.46K) | (40.34K) | 93.56M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.95M | (39.05M) | (1.3M) | (234.54K) | (360.49K) |
| Free Cash Flow | (91.87M) | (103.8M) | (51.66M) | (51.76M) | (45.79M) |
Relmada Therapeutics, Inc.
NASDAQ:RLMD
Intrinsic Alpha fair value
Locked
Current Price
$2.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.